Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2008

01-09-2008 | Letter to the Editor

Late-onset neutropenia following viral bone marrow depression after rituximab therapy

Authors: Maximilian Christopeit, Ursula Haak, Gerhard Behre

Published in: Annals of Hematology | Issue 9/2008

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, Takahashi K, Oshima K, Kanda Y, Chiba S, Motokura T, Kurokawa M (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18:364–369PubMedCrossRef
2.
Voog E, Morschhauser F, Solal-Celigny P (2003) Neutropenia in patients treated with rituximab. N Engl J Med 348:2691–2694PubMedCrossRef
3.
Benyunes M, Multani P, Saunders A (2003) Neutropenia in patients treated with rituximab [response letter]. N Engl J Med 348:2694
4.
Hartmann JT, Meisinger I, Kröber SM, Weisel K, Klingel K, Kanz L (2006) Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. Haematologica 91:16
Metadata
Title
Late-onset neutropenia following viral bone marrow depression after rituximab therapy
Authors
Maximilian Christopeit
Ursula Haak
Gerhard Behre
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0455-2

Other articles of this Issue 9/2008

Annals of Hematology 9/2008 Go to the issue

Original Article

Congenital dyserythropoietic anemia in a Chinese family with a mutation of the CDAN1-gene

Original Article

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

Letter to the Editor

Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature

Original Article

Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death

Letter to the Editor

JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia

Letter to the Editor

Influence of rituximab–CHOP therapy on clinical course and autoimmune parameters in rheumatoid arthritis associated with diffuse large B cell non-Hodgkin lymphoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits